Gene therapy for heart failure with preserved ejection fraction

18 May 2025 (14:05 - 14:15)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Doctor Marat Fudim

Duke Clinical Research Institute, Durham (United States of America)

5 More presentations in this session

Presentation thumbnail

Safety and tolerability of diuretics withdrawal in patients with heart failure with reduced ejection fraction. REDICAE trial

Doctor J. Torres Zamudio (Cordoba, ES)

Presentation thumbnail

Oral iron supplementation with ferric maltol improves iron deficiency anaemia in patients with chronic heart failure

Professor T. Kempf (Hannover, DE)

Presentation thumbnail

NAN-CS101: A first-in-human Phase 1 open-label dose-escalation study of AB-1002 gene therapy for the treatment of NYHA class III heart failure

Doctor R. Hajjar (Boston, US)

Presentation thumbnail

Finerenone on arterial stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease: a randomized placebo-controlled mechanistic trial (FIVE-STAR)

Professor A. Tanaka (Saga, JP)

Presentation thumbnail

Cardio-microcurrent device for chronic heart failure: results from the C-MIC II randomized controlled trial

Professor S. Anker (Berlin, DE)

Access the full session

Session thumbnail

Late-breaking clinical trials in chronic heart failure

The Event

Event poster

Heart Failure 2025

18 May 2025 14:05 CET

You may be interested in

Congress Presentation

Targets for gene therapy in heart failure and cardiomyopathies

Congress Presentation

Gene therapy targeting cardiac remodelling in heart failure and cardiomyopathies

Congress Presentation

NAN-CS101: A first-in-human Phase 1 open-label dose-escalation study of AB-1002 gene therapy for the treatment of NYHA class III heart failure

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources